Expectations for Expanding an Innovative Cancer Drug Portfolio
SK Biopharm has embarked on globalizing its research and development (R&D) by recruiting researchers from GlaxoSmithKline (GSK) to its local subsidiary in the United States.
On the 17th, SK Biopharm announced that its US research-focused subsidiary, SK Life Science Labs, has hired Dr. Ryan Krueger as Head of Biology and Dr. Steven Knight as Head of Chemistry.
Dr. Krueger is an expert in cancer biology and epigenetics who has led R&D at GSK and biotech companies, while Dr. Knight worked at GSK for over 25 years, leading the development of new drug candidates based on small molecules and targeted protein degradation (TPD) therapies.
SK Biopharm stated that it is researching radiopharmaceutical therapies (RPT) and TPD as next-generation modalities (therapeutic approaches), and expects to expand its clinical-stage innovative oncology portfolio by 2029 based on these new hires.
SK Life Science, SK Biopharm’s US local subsidiary, also recruited Dr. Evelyn Shi, a pediatric neurology expert, as Medical Director (MD) of CNS clinical division, and Dr. Marcus Leppler, an oncology expert, as MD of oncology and RPT clinical division.
Lee Dong-hoon, President of SK Biopharm, said, "This talent acquisition is an important part of our strategy to further strengthen SK Biopharm’s global R&D competitiveness. Through world-class researchers, we will accelerate the development of innovative cancer therapies and contribute to achieving our goal of becoming a global big biotech company."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
